Japan: PMDA and MHLW — who inspects your site, and who decides?

Japan has a distinctive pharmaceutical inspection system in which inspection activities and administrative responsibilities are distributed among the Pharmaceuticals and Medical Devices Agency (PMDA), the Ministry of Health, Labour and Welfare (MHLW), and Japan’s 47 prefectural governments.

For foreign pharmaceutical manufacturers, understanding this division is essential. PMDA conducts GMP inspections of overseas manufacturing sites and reports the results to MHLW, while administrative powers are exercised by the competent authority under the applicable legal framework.

This article examines how the Japanese system operates, who conducts inspections, how inspection procedures are organised, and what overseas manufacturers should consider when preparing to enter the Japanese market.

Who sets the requirements?

Japan’s pharmaceutical GMP framework is based on the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (the PMD Act).

The principal regulatory instruments include:

  • PMD Act: The Act establishes the legal framework for pharmaceutical regulation, manufacturing activities, inspections and administrative responsibilities.
  • MHLW ministerial ordinances: Detailed manufacturing and quality control requirements are established through ministerial ordinances. The principal instrument for pharmaceuticals and quasi-drugs is Ministerial Ordinance No. 179 of 2004, which also contains provisions specifically addressing active pharmaceutical ingredients (APIs).
  • International harmonisation: Japan participates in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Japanese GMP requirements incorporate internationally recognised principles and practices.

Who conducts inspections?

Three groups of authorities participate in Japan’s pharmaceutical GMP inspection system.

MHLW — national regulatory authority

The Ministry of Health, Labour and Welfare is responsible for pharmaceutical policy, regulatory oversight and administrative measures.

Its responsibilities include licensing and marketing authorisation functions, regulatory supervision and enforcement. Licensing and inspection responsibilities are shared with PMDA and the prefectural authorities, depending on the product category and applicable legal provisions.

PMDA — inspection and scientific assessment

The Pharmaceuticals and Medical Devices Agency is an independent administrative agency operating under the MHLW framework.

Its responsibilities include scientific assessment of applications and GMP inspections of manufacturing facilities, including overseas sites. PMDA also conducts inspections associated with the accreditation of foreign manufacturers.

An important distinction is that PMDA’s inspection findings and the administrative measures taken by the competent authority are separate elements of the regulatory process. For foreign-site GMP compliance inspections, PMDA reports its results to MHLW.

The 47 prefectural governments — regional inspection authorities

Prefectural governments have delegated responsibilities for domestic pharmaceutical manufacturers, including manufacturing-site licensing, GMP inspections and administrative enforcement within their respective jurisdictions, subject to exceptions for certain product categories and inspections assigned to MHLW or PMDA.

The allocation of inspection responsibilities depends on the manufacturing site, product category and type of inspection.

The Japanese system therefore does not operate through a single national inspectorate. PMDA and prefectural authorities have distinct responsibilities, while MHLW provides national regulatory oversight.

One important feature is that GMP compliance is linked to specific products and their approved manufacturing arrangements. Inspection requirements apply to the relevant manufacturing sites and activities identified in the marketing authorisation application, rather than automatically establishing a universal GMP status for an entire manufacturing organisation.

Grounds and types of inspection

GMP compliance is a prerequisite for pharmaceutical marketing approval in Japan.

The inspection framework includes several types of assessment:

Application-based inspections

  • Inspections conducted in connection with applications for new marketing authorisations or applications for partial changes to approved information.
  • Periodic inspections, normally conducted every five years after marketing approval.
  • Inspections associated with Post-Approval Change Management Protocols (PACMPs).
  • Product category-based inspections, introduced in August 2021.

Inspections not based on applications

  • Planned inspections conducted according to risk analysis.
  • For-cause inspections.

The product category-based inspection system

An important development in the Japanese system was the introduction of product category-based inspections in August 2021.

Under this optional approach, manufacturers can apply for an inspection covering a particular category of manufacturing process rather than relying exclusively on product-by-product periodic inspections.

A certificate is issued for the relevant manufacturing-process category and is valid for three years.

During the certificate’s validity period, periodic inspections for individual products belonging to that category may be omitted, subject to the applicable conditions. The initial periodic inspection for new drugs cannot be omitted under this arrangement.

This mechanism is intended to improve inspection efficiency and reduce repeated inspections of manufacturing sites producing multiple products for different marketing authorisation holders.

On-site or document-based inspection?

For foreign manufacturing sites, PMDA’s general principle is an on-site GMP inspection.

However, the Agency may decide to conduct a document-based inspection, also referred to as a desktop inspection.

The decision takes account of factors including:

  • The risk associated with the product.
  • The GMP standards and their implementation in the manufacturing site’s country.
  • The site’s GMP compliance history and status.
  • The supporting documentation submitted before the inspection.

International regulatory cooperation is also relevant. In particular, inspection reports and GMP certificates issued by authorities in countries covered by mutual recognition agreements (MRAs) or memoranda of understanding (MOUs) can form part of the documentation submitted to PMDA.

However, the existence of an MRA or MOU does not automatically guarantee that a document-based inspection will be selected.

Who applies for the inspection?

For overseas manufacturing sites, the inspection application is submitted by the Japanese marketing authorisation holder (MAH), rather than directly by the foreign manufacturer.

The foreign manufacturer must also hold the relevant accreditation from MHLW as a foreign manufacturer. The accreditation procedure is separate from the application for GMP compliance inspection.

The general procedure is as follows:

  1. The Japanese MAH submits the application for GMP compliance inspection.
  2. PMDA reviews the application and determines the inspection approach.
  3. An on-site inspection is normally conducted, unless a document-based inspection is considered appropriate.
  4. PMDA reports the inspection results to MHLW using the prescribed GMP Compliance Inspection Result Notification.
  5. The MAH receives a copy of the notification. For on-site inspections, the foreign manufacturer also receives the relevant inspection report. No copy of the inspection report is issued to the foreign manufacturer following a document-based inspection.
  6. Where deficiencies are identified, the manufacturer is expected to submit appropriate improvement documentation.

The application and supporting documents concerning foreign manufacturing sites must be prepared in Japanese. Where extensive foreign-language documentation is involved, Japanese-language summaries may be accepted for relevant supporting materials.

The Master File system for APIs

Japan operates a Master File system for pharmaceutical substances and other relevant materials.

A foreign API manufacturer can register a Drug Master File (DMF), providing information about the substance and its manufacturing arrangements. However, foreign manufacturers cannot apply directly to PMDA and must appoint an in-country caretaker in Japan to handle the relevant administrative procedures.

The foreign manufacturer does not independently submit a marketing authorisation application for the finished medicinal product. The Japanese regulatory process involves the relevant domestic applicant or representative.

The Master File is considered during the assessment of the medicinal product that references it. Registration of the file and its subsequent assessment in connection with a product application are distinct regulatory steps.

What does the inspection outcome mean?

GMP compliance is a prerequisite for marketing authorisation in Japan. An unsatisfactory inspection outcome can therefore prevent the relevant product from receiving approval.

It is also important to distinguish inspection findings from administrative decisions.

PMDA conducts inspections and reports the results. Administrative measures, including orders and the suspension or withdrawal of relevant licences and authorisations, fall within the powers of the competent authority — MHLW or the relevant prefectural government, depending on the applicable jurisdiction and legal basis.

Manufacturers should therefore distinguish between:

  • Inspection report and identified deficiencies.
  • Formal GMP compliance determination.
  • Subsequent administrative measures taken by the competent authority.

These are related but legally distinct elements of the regulatory process.

International recognition and regulatory cooperation

Japan participates in several international arrangements that influence its GMP inspection activities.

PIC/S

In July 2014, Japan’s pharmaceutical GMP inspection authorities — MHLW, PMDA and the 47 prefectural governments — joined PIC/S as a single participating authority.

The EU–Japan mutual recognition agreement

The EU–Japan MRA on GMP has been operational since 29 May 2004.

In July 2018, its scope was extended to include sterile medicinal products, APIs and certain biological products, including vaccines and immunologicals.

The agreement allows the EU and Japanese authorities to rely on each other’s GMP inspections, waive certain batch-testing requirements and exchange information about inspections and quality defects for medicinal products within the agreement’s scope. The MRA covers human medicines only and does not apply to veterinary medicines.

For manufacturers exporting products to Japan from the EU, the agreement provides an important framework for regulatory cooperation and the use of existing inspection evidence.

EudraGMDP

Japan’s MHLW and PMDA also cooperate with the European Medicines Agency through EudraGMDP. Under the EU–Japan MRA, they can enter GMP compliance information concerning Japanese manufacturers into the database, enabling European and Japanese authorities to access relevant compliance information electronically.

The database provides a mechanism for sharing relevant information about manufacturing-site compliance between participating regulatory authorities.

Checklist before a PMDA inspection

Foreign manufacturers preparing for the Japanese market should consider the following points:

  • Manufacturing-site status: Confirm whether the site is domestic or overseas and whether the required foreign manufacturer accreditation is in place.
  • Inspection type: Establish whether the inspection is pre-approval, periodic, product category-based or for-cause.
  • Inspection approach: Determine whether an on-site inspection or a document-based assessment is expected.
  • Japanese MAH: Confirm who will submit the inspection application and coordinate the Japanese regulatory process.
  • Product and site linkage: Identify all manufacturing sites and relevant external testing laboratories included in the application.
  • API Master File: Where applicable, confirm that the DMF is registered, current and correctly referenced in the product application.
  • Inspection history: Prepare relevant inspection reports, GMP certificates and supporting compliance documentation, including evidence from authorities in MRA or MOU countries where applicable.
  • Administrative responsibilities: Understand the distinction between PMDA inspection findings and the subsequent decisions of MHLW or the competent prefectural authority.

Japan’s inspection system is based on a division of regulatory responsibilities, product-specific compliance assessments and extensive international cooperation. For overseas manufacturers, understanding who conducts the inspection, who submits the application and which authority has the power to make administrative decisions is essential to navigating the Japanese pharmaceutical market.

The next article in the series examines China and the NMPA — the regulator that rebuilt its inspection system in a single decade.

POPULAR